Search

Author/Creator Mego, Michal

21. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. (March 2023)

Authors:
Antonelli, Luca; Ardizzone, Davide; Ravi, Praful; Bagrodia, Aditya; Mego, Michal; Daneshmand, Siamak; Nicolai, Nicola; Nazzani, Sebastiano; Giannatempo, Patrizia; Franza, Andrea; Heidenreich, Axel; Paffenholz, Pia; Saoud, Ragheed; Eggener, Scott; Ho, Matthew; Oswald, Nathaniel; Olson, Kathleen; T...
Journal:
European journal of cancer
Issue:
Volume 182(2023)
Page Start:
144
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

22. Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. (March 2022)

Authors:
Dieckmann, Klaus-Peter; Pokrivcak, Tomas; Geczi, Lajos; Niehaus, David; Dralle-Filiz, Inken; Matthies, Cord; Dienes, Tamas; Zschäbitz, Stefanie; Paffenholz, Pia; Gschliesser, Tanja; Pichler, Renate; Mego, Michal; Bader, Pia; Zengerling, Friedemann; Heinzelbecker, Julia; Krausewitz, Philipp; Krege...
Journal:
Therapeutic advances in medical oncology
Issue:
Volume 14(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗